<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03217734</url>
  </required_header>
  <id_info>
    <org_study_id>A16-241</org_study_id>
    <nct_id>NCT03217734</nct_id>
  </id_info>
  <brief_title>MAP Study: Methotrexate and Adalimumab in Psoriasis</brief_title>
  <acronym>MAP</acronym>
  <official_title>MAP Study (Methotrexate and Adalimumab in Psoriasis): Adalimumab vs. Combination Adalimumab and Methotrexate in Psoriasis: Efficacy and Anti-Adalimumab Antibody Formation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeffrey J Crowley MD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bakersfield Dermatology &amp; Skin Cancer Medical Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the efficacy and safety of ADA compared to ADA/MTX in patient with Psoriasis. Compare
      Anti-ADA antibody formation and serum ADA levels in patients on ADA compared with those on
      combination ADA and MTX.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assess the efficacy and safety of ADA compared to ADA/MTX in patients with psoriasis. Many
      studies of ADA in rheumatoid and psoriatic arthritis have allowed patients on stable doses of
      MTX to continue on MTX while being treated with ADA. There has been no prospective trial of
      MTX and ADA concomitantly in psoriasis. Safety of ADA monotherapy vs. combination ADA/MTX
      will be compared.

      Compare anti-ADA antibody formation and serum ADA levels in patients on ADA compared with
      those on combination ADA and MTX. ADA is a fully human monoclonal antibody to TNF-a. More
      recent advances in detection of ADA antibodies have shown that many patients develop
      antibodies to ADA while on treatment and some of these antibodies are neutralizing. The
      presence of anti-ADA antibodies has been correlated with loss of therapeutic response in many
      disease states.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 10, 2017</start_date>
  <completion_date type="Anticipated">October 10, 2018</completion_date>
  <primary_completion_date type="Anticipated">April 10, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PASI Change</measure>
    <time_frame>16 weeks</time_frame>
    <description>Mean percent change in PASI from 16 Weeks to Baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ADA/Anti ADA Antibodies</measure>
    <time_frame>16 weeks</time_frame>
    <description>Antibodies to Adalimumab at 16 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>ADA and Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Adalimumab 40 mg, Subcutaneous, Bi-Weekly, 16 Weeks Placebo, Tablet, Oral, Weekly, 16 Weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADA and MTX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adalimumab 40 mg, Subcutaneous, Bi-Weekly, 16 Weeks Methotrexate, 2.5 mg Tablet, 10 mg Weekly, Oral, 16 Weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>Subcutaneous Injection</description>
    <arm_group_label>ADA and Placebo</arm_group_label>
    <arm_group_label>ADA and MTX</arm_group_label>
    <other_name>Humira</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Oral Tablet</description>
    <arm_group_label>ADA and MTX</arm_group_label>
    <other_name>MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral Tablet</description>
    <arm_group_label>ADA and Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female adult (≥ 18yrs) with a diagnosis of moderate to severe plaque psoriasis

          2. Subject must have ≥ 10% body surface area involvement

          3. Subject must have psoriasis area and severity index (PASI) ≥12

          4. Subject has stable psoriasis of at least six months' duration

          5. Male subjects must agree to use a reliable form of birth control during the study and
             for 180 days after the last dose of study drug. Male subjects must not donate sperm
             during the study or for 180 days after the last dose of study drug. If female, subject
             is either not of childbearing potential (postmenopausal for at least 1 year or
             surgically sterile) or is of childbearing potential and is using approved method of
             birth control throughout study and for 180 days after last dose of study drug.
             Approved methods of birth control include the following:

               1. Condoms, sponge, foams, jellies, diaphragm, or intrauterine device (IUD)

               2. Hormonal contraceptives for 90 days prior to study drug administration

               3. A vasectomized partner

          6. Subject has negative PPD tuberculosis skin test at screening assessment.

          7. Subject must be able and willing to provide written informed consent and comply with
             requirements of this study protocol.

        Exclusion Criteria

          1. Diagnosis or presence of guttate, erythrodermic or pustular psoriasis

          2. Any previous exposure to ADA including biosimilar ADA

          3. Moderate to high strength topical steroids (class 4 or greater) or Vitamin D analogues
             within one week of study entry

          4. Oral systemic therapy (methotrexate, cyclosporine, apremilast, acitretin) within 8
             weeks of study entry

          5. Previous intolerance or adverse reaction to MTX

          6. Phototherapy of any type within 4 weeks of study entry (narrowband UVB, psoralen-UVA,
             308 nM LASER, commercial tanning units)

          7. IL-12/23 inhibitors (ustekinumab) and any IL-23 inhibitor (guselkumab, tildrakizumab,
             risankizumab) within 12 weeks of baseline

          8. Other biologic agents within 8 weeks of study entry

          9. History of chronic liver disease, hepatitis, or alcohol abuse

         10. Chronic use of any concomitant medication which has a significant potential for
             interaction with MTX (e.g. sulfa antibiotics, chronic non-steroidal anti-inflammatory
             (NSAID) use)

         11. History of tuberculosis, opportunistic infections, or any active infection at
             screening

         12. Elevated liver enzymes (AST, ALT, ≥1.5 times normal at screening)

         13. Serum creatinine ≥1.5 (at screening)

         14. Any other laboratory abnormality that would pose a concern for the investigator

         15. Daily alcohol use or consumption of more than four alcoholic drinks (4 ounces) in one
             24 hour period

         16. Patients who test positive for hepatitis B or C exposure (previous vaccination to
             Hepatitis B is allowed)

         17. Cancer within the last five years is exclusionary with the exception of treated
             cutaneous basal cell carcinoma or squamous cell carcinoma or low-grade cervical
             intraepithelial neoplasia.

         18. Any patient that is deemed by the investigator to be at a safety risk for the
             intervention in this trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey J Crowley, MD</last_name>
    <role>Study Director</role>
    <affiliation>Bakersfield Dermatology and Skin Cancer Medical Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeffrey J Crowley, MD</last_name>
    <phone>661-327-3756</phone>
    <email>crowley415@aol.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chali M Garcia</last_name>
    <phone>661-327-3756</phone>
    <email>chalig@bakersfieldderm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bakersfield Dermatology and Skin Cancer Medical Group</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chali M Garcia</last_name>
      <phone>661-327-3756</phone>
      <email>chalig@bakersfieldderm.com</email>
    </contact>
    <contact_backup>
      <last_name>Stacey Underhill</last_name>
      <phone>661-327-3756</phone>
      <email>sunderhill@bakersfieldderm.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jeffrey J Crowley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Science Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Giles</last_name>
      <phone>310-828-8887</phone>
      <email>mgiles@csird.com</email>
    </contact>
    <investigator>
      <last_name>Paul S Yamauchi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DermAssociates, PC</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Miller</last_name>
      <phone>301-355-3183</phone>
      <email>lmiller@dermassociates.com</email>
    </contact>
    <contact_backup>
      <last_name>Thomas M Blondo</last_name>
      <phone>301-355-3183</phone>
      <email>tblondo@dermassociates.com</email>
    </contact_backup>
    <investigator>
      <last_name>Benjamin N Lockshin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Janet C Lin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Modern Research Associates, PLLC</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacy Reed</last_name>
      <phone>214-361-2008</phone>
      <email>stacy@mradallas.com</email>
    </contact>
    <contact_backup>
      <last_name>Valencia Garcia</last_name>
      <phone>214-361-2008</phone>
      <email>valencia@mradallas.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jennifer C Cather, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Melodie Young, NP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2017</study_first_submitted>
  <study_first_submitted_qc>July 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2017</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Bakersfield Dermatology &amp; Skin Cancer Medical Group</investigator_affiliation>
    <investigator_full_name>Jeffrey J Crowley MD</investigator_full_name>
    <investigator_title>Jeffrey J Crowley, MD, Prinicipal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

